Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 101Carcinoma, Non-Small-Cell Lung 88Carcinoma, Renal Cell 54Neoplasm Metastasis 37Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 32Carcinoma, Hepatocellular 32Lung Neoplasms 31Hodgkin Disease 25Neoplasms 24Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Carcinoma, Transitional Cell 20Breast Neoplasms 19Stomach Neoplasms 17Brain Neoplasms 17Prostatic Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 15Multiple Myeloma 14Head and Neck Neoplasms 14Esophageal Neoplasms 14Glioblastoma 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Neuroendocrine Tumors 10Lymphoma 10Recurrence 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

Nivolumab 2Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Various Advanced Cancer × Nivolumab × Clear all
NCT02387996 2022-11-01

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Bristol-Myers Squibb

Phase 2 Completed
270 enrolled 14 charts

Various Advanced Cancer

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed
166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡